RhumbLine Advisers’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
2024
Q2
$3.59M Sell
2024
Q1
$4.36M Buy
2023
Q4
$4M Buy
2023
Q3
$1.91M Sell
2023
Q2
$2.81M Buy
2023
Q1
$2.04M Buy
2022
Q4
$2.52M Buy
2022
Q3
$1.97M Buy
2022
Q2
$1.65M Buy
2022
Q1
$1.44M Buy
2021
Q4
$1.19M Sell
2021
Q3
$1.08M Buy
2021
Q2
$724K Buy